Currently, new formulations are being developed for CA administration in different pathologies, such as transferrin (Tf)-modified nanoparticles (NPs) loaded with CA for Alzheimer’s disease (AD) [152], topical cream with nanostructured lipid carriers (NLCs) loaded with CA for anti-inflammatory action [153], and poloxamer 407 designed to improve the stability of caffeic acid in the stomach [154]. This evidence concerns the gene TF and early-onset autosomal dominant Alzheimer disease.